ArticleInternational journal of nanomedicine2017
Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Nanoparticles in influenza research: a bibliometric analysis of global trends (2005 - 2025).Frontiers in immunology · 2026Pooled it
- Selenium nanoparticles: Eco-friendly synthesis, biological activities and biomedical applications - A comprehensive review.Materials today. Bio · 2026Review
- Selenium-derived bioactive enablers for advanced therapies: From molecular redox modulation to broad-spectrum disease applications.Bioactive materials · 2026Review
- Selenoprotein M Inhibits the Replication of Influenza A Virus by Regulating Reactive Oxygen Species Levels.Life (Basel, Switzerland) · 2025Article
- Synthesis and Biomedical Based Applications of Selenium Nanoparticles: A Comprehensive Review.Indian journal of microbiology · 2025Article
- Nano Selenium: A Promising Solution for Infectious Diseases - Current Status and Future Prospects.Current pharmaceutical design · 2025Review
- Beneficial Effects of Selenium and Its Supplementation on Carcinogenesis and the Use of Nanoselenium in the Treatment of Malignant Tumors.International journal of molecular sciences · 2024Review
- Optimization of fermentation parameters to improve the biosynthesis of selenium nanoparticles by Bacillus licheniformis F1 and its comprehensive application.BMC microbiology · 2024Article
- Recent advances in the therapeutic applications of selenium nanoparticles.Molecular biology reports · 2024Review
- Lectins as the prominent potential to deliver bioactive metal nanoparticles by recognizing cell surface glycans.Heliyon · 2024Review
- Nanoparticle‑based antiviral strategies to combat the influenza virus (Review).Biomedical reports · 2024Review
- Green synthesis of MnOVirology journal · 2024Article
- Biocompatible Iron Oxide Nanoparticles Display Antiviral Activity Against Two Different Respiratory Viruses in Mice.International journal of nanomedicine · 2024Article
- Selenadiazole Inhibited Adenovirus-Induced Apoptosis through the Oxidative-Damage-Mediated Bcl-2/Stat 3/NF-κB Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Nano-based techniques: A revolutionary approach to prevent covid-19 and enhancing human awareness.Journal of drug delivery science and technology · 2023Review
- Antimicrobial and anti-viral effects of selenium nanoparticles and selenoprotein based strategies: COVID-19 and beyond.Journal of drug delivery science and technology · 2023Review
- A Review of the Antibacterial, Fungicidal and Antiviral Properties of Selenium Nanoparticles.Materials (Basel, Switzerland) · 2023Review
- Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants.Journal of nanobiotechnology · 2023Review
- Anticancer activity of lactoferrin-coated biosynthesized selenium nanoparticles for combating different human cancer cells via mediating apoptotic effects.Scientific reports · 2023Article
- Inhibition of H1N1 Influenza Virus-induced Apoptosis by Ebselen Through ROS-mediated ATM/ATR Signaling Pathways.Biological trace element research · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an effective antiviral agent, the clinical application of oseltamivir (OTV) is limited by the appearance of drug-resistant viruses. Due to their low toxicity and excellent activity, the antiviral capabilities of selenium nanoparticles (SeNPs) has attracted increasing attention in recent years. To overcome the limitation of drug resistance, the use of modified NPs with biologics to explore novel anti-influenza drugs is developing rapidly. In this study, OTV surface-modified SeNPs with superior antiviral properties and restriction on drug resistance were synthesized. OTV decoration of SeNPs (Se@OTV) obviously inhibited H1N1 infection and had less toxicity. Se@OTV interfered with the H1N1 influenza virus to host cells through inhibiting the activity of hemagglutinin and neuraminidase. The mechanism was that Se@OTV was able to prevent H1N1 from infecting MDCK cells and block chromatin condensation and DNA fragmentation. Furthermore, Se@OTV inhibited the generation of reactive oxygen species and activation of p53 phosphorylation and Akt. These results demonstrate that Se@OTV is a promising efficient antiviral pharmaceutical for H1N1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.